N-of-One Selected by OncoDNA to Provide Clinical Interpreta?tion for Next-Gener?ation Sequencing Tests Worldwide

N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, has announced an agreement with OncoDNA, the first company in Europe to provide personalized medicine in oncology based on the molecular analysis of each patient’s tumour. Under this agreement, N-of-One will provide the clinical interpretation for all of OncoDNA’s next-generation sequencing (NGS) and other molecular tests done for patients throughout Europe, the Middle East, and in other parts of the world. Fhttp://www.oncodna.cominancial terms of the agreement are not disclosed.

OncoDNA provides comprehensive tumour profiling services to assist medical doctors in their treatment choices and provide better monitoring of the evolution of patient tumours. The lab is led by a team of highly experienced experts in DNA sequencing and diagnostic analyses in oncology.

N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge and insights related to the mutation profile of a tumour identified by sequencing linking this knowledge to relevant therapeutic strategies, including clinical trials.

“We selected N-of-One for their best-in-class clinical interpretation and their ability to integrate multiple types of molecular test results into a single clinical report with very fast turnaround times,” said Jean-Pol Detiffe, CEO of OncoDNA.  “N-of-One’s clinical interpretation uniquely provides the clinician with actionable insights and knowledge that can be used at the point of care.”

“OncoDNA’s industry-leading, molecular diagnostic solutions, coupled with N-of-One’s deep expertise in clinical interpretation in oncology, will enable broader patient access worldwide to personalized cancer treatment in a scalable, cost-effective manner,” said Chris Cournoyer, CEO of N-of-One.